Srinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.
Ramaprasad Srinivasan, MD, PhD, staff clinician in the Urologic Oncology Branch, National Cancer Institute, discusses the complex heterogeneity of kidney cancer. Srinivasan says because there are so many types of kidney cancers, medical professionals must tailor their treatment to each specific patient.
Oncologists should also seek out and consult other practices who have experience in dealing with specific, possibly rare, types of kidney cancers.
Srinivasan says enrolling patients in clinical trials that best represents their type of kidney cancer is an appropriate course of action for treatment.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen